KCM
GILD icon

Kingdon Capital Management’s Gilead Sciences GILD Stock Holding History

Kingdon Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100,000
Closed -$5.95M – 83
2022
Q1 		$5.95M Buy
+100,000
New +$6.39M 0.62% 42

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kingdon Capital Management's GILD Position: Q4 2016 in Review

Kingdon Capital Management sold out of Gilead Sciences (GILD) in Q4 2016, closing a stake of 58,668 shares — an estimated $4.64M sold.

Kingdon Capital Management first reported a position in GILD in Q2 2013 and held it in 6 quarters. The position peaked at $11.6M in Q4 2013. 1,573 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

  • Kingdon Capital Management reported no remaining Gilead Sciences position as of Q4 2016 after selling out during the quarter.
  • Kingdon Capital Management sold 58,668 Gilead Sciences shares in Q4 2016, an estimated $4.64M.
  • Kingdon Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 6 quarters.
  • Kingdon Capital Management's Gilead Sciences position peaked at $11.6M in Q4 2013.
  • 1,573 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on Kingdon Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.